Response assessment of melanoma brain metastases treated by stereotactic radiotherapy or immunotherapy or both: A comparison of RECIST 1.1, RANO and iRANO criteria

Background null The evaluation of response for brain metastases (BM) may be challenging in the context of treatment by stereotactic radiotherapy (SRT) or immunotherapy or both, which represent major therapeutic options for melanoma BM. null null null Methods null We reviewed clinical and neuroimaging data of 62 melanoma patients with newly diagnosed BM treated by the combination of immunotherapy and SRT (n = 33, group A), immunotherapy alone...